Forgot Password?
Return to Course Listing

CME: Diffuse Large B-Cell Lymphoma (DLBCL): Therapeutic Updates and Best Practices


Activity Description / Statement of Need:

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma (NHL), making up just under a third of NHL cases. In the U.S., there are roughly 7 cases of DLBCL per 100,000 patients per year, with an average age of presentation at 64 years old. The pathophysiology of DLBCL is complex and not fully understood; but is characterized by a widespread increase of very large, mature B-cells arising from various gene mutations. DLBCL is heterogenous group of tumors and includes many diverse subtypes based on location, presence of other cells within the tumor, and whether the patient has other related illnesses. Advanced age, immunodeficiency, and Epstein-Barr virus are associated risk factors for DLBCL.

Target Audience:

The following healthcare professionals: hematologists and oncologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with DLBCL.

This program is supported by educational grants from AMGEN.

Release Date: March 16, 2018 -- Expiration Date: March 16, 2020

Faculty: Jonathan Kolitz, MD


Faculty introduction, disclosures 

Epidemiology and diagnosis of DLBCL [Learning objective #1]

  • The most affected: a demographic review
  • Risk factors
  • Clinical features, presentation, and pathophysiology
    • Patient case(s)

Management of DLBCL: current guidelines, agents, and monitoring [Learning objectives #2, 3, & 4]

  • Present therapy:
    • R-CHOP
    • Alternative approaches in special populations
    • Monitoring
    • Investigational and emerging therapies (CD19, CD20, CD30, and Bruton’s tyrosine kinase targeting)
    • Best practice and clinical pearls
    • Gaps in care
    • Patient cases

Summary, conclusions, and best practice recap

Learning Objectives

By the end of the session the participant will be able to:

  • Recognize and describe those characteristics that play a role in determining the staging, prognosis, and diagnosis of diffuse large B-cell lymphoma (DLBCL)
  • Describe the most approaches to DLBCL management and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence and evidence-based treatment guidelines supporting them
  • Summarize the risk-benefit profiles of current and emerging therapies for the treatment of DLBCL
  • Describe the challenges and barriers to care associated with treating patients with DLBCL



Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.


Faculty: Jonathan E. Kolitz, M.D.
Professor of Medicine
Zucker School of Medicine at Northwell/Hofstra
Monter Cancer Center
Lake Success and Happaugue, NY


Faculty Disclosure:  Jonathan Kolitz, MD is on an advisory board for Novartis


Disclosures of Educational Planners: Charles Turck, PharmD has no relevant financial disclosures.


Commercial Support Disclosure: This program is supported by educational grants from AMGEN.


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Multiple Myeloma Pharmacotherapy: Therapeutic Updates, Best Practices, and Emerging Treatment Options

Acute Lymphoblastic Leukemia (ALL): Highlights from the 2016 American Society of Hematology (ASH 2016): Take-Aways, Emerging Practice Changes, and Barriers to their Implementation

Advancing Treatment Strategies in Acute Lymphoblastic Leukemia (ALL) Drug Therapy

Advancing Treatment Strategies in Multiple Myeloma (MM) Drug Therapy